Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Nanotechnology - Page 2

Nanotechnology

World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine | WHO

World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine

On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…

Read More World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccineContinue

Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine | WHO

Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine

On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…

Read More Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccineContinue

Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine

On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…

Read More Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccineContinue

Llama antibodies could help fight SARS-CoV-2 variants
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Therapeutics

Llama antibodies could help fight SARS-CoV-2 variants

On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…

Read More Llama antibodies could help fight SARS-CoV-2 variantsContinue

Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in the Philippines
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in the Philippines

On Nov. 17, 2021, Novavax and and Serum Institute of India announced that the Philippine Food and Drug…

Read More Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in the PhilippinesContinue

Zosano Pharma announced successful formulation of COVID-19 vaccine candidate on its microneedle patch system
Biotechnology | COVID-19 | FDA | Infectious Disease | Nanotechnology | Vaccine

Zosano Pharma announced successful formulation of COVID-19 vaccine candidate on its microneedle patch system

On Nov. 17, 2021, Zosano Pharma announced that the Philippine Food and Drug Administration had granted emergency use…

Read More Zosano Pharma announced successful formulation of COVID-19 vaccine candidate on its microneedle patch systemContinue

Novavax announced submission of Biologics License Application in South Korea for approval of NVX-CoV2373
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced submission of Biologics License Application in South Korea for approval of NVX-CoV2373

On Nov. 15, 2021, Novavax and SK bioscience announced submission of a Biologics License Application (BLA) for Novavax’…

Read More Novavax announced submission of Biologics License Application in South Korea for approval of NVX-CoV2373Continue

Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic Intensifies
Life Science History | Nanotechnology

Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic Intensifies

On Sept. 21, 2021, the Medicines Patent Pool (MPP) announced that it had signed a licence agreement with…

Read More Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic IntensifiesContinue

Novavax filed COVID-19 vaccine for Emergency Use listing with World Health Organization
COVID-19 | Nanotechnology | Vaccine | WHO

Novavax filed COVID-19 vaccine for Emergency Use listing with World Health Organization

On Nov. 4, 2021, Novavax announced the completion of its rolling submission to the World Health Organization (WHO)…

Read More Novavax filed COVID-19 vaccine for Emergency Use listing with World Health OrganizationContinue

Novavax and Serum Institute of India receive Emergency Use Authorization for COVID-19 vaccine in Indonesia
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax and Serum Institute of India receive Emergency Use Authorization for COVID-19 vaccine in Indonesia

On Nov. 1, 2021, Novavax and Serum Institute of India announced that the National Agency of Drug and…

Read More Novavax and Serum Institute of India receive Emergency Use Authorization for COVID-19 vaccine in IndonesiaContinue

Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine | WHO

Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine

On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the…

Read More Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccineContinue

The Medicines Patent Pool secured its first licence for malaria, tuberculosis and hepatitis C
Life Science History | Nanotechnology

The Medicines Patent Pool secured its first licence for malaria, tuberculosis and hepatitis C

On Sept. 21, 2021, the Medicines Patent Pool (MPP) announced that it had signed a licence agreement with…

Read More The Medicines Patent Pool secured its first licence for malaria, tuberculosis and hepatitis CContinue

Novavax included in University of Oxford Com-COV3 study comparing mixed COVID-19 vaccine in adolescents
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax included in University of Oxford Com-COV3 study comparing mixed COVID-19 vaccine in adolescents

On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing…

Read More Novavax included in University of Oxford Com-COV3 study comparing mixed COVID-19 vaccine in adolescentsContinue

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody

On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…

Read More Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibodyContinue

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine

On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…

Read More Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccineContinue

Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial

On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…

Read More Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trialContinue

NIH launched clinical trial of universal influenza vaccine candidate
Biotechnology | Infectious Disease | Influenza | Nanotechnology | NIH | Vaccine

NIH launched clinical trial of universal influenza vaccine candidate

On Jun. 1, 2021, the National Institutes of Health (NIH) announced the first-in-human, Phase 1 trial assessing the…

Read More NIH launched clinical trial of universal influenza vaccine candidateContinue

The Priestley Medal was awarded to Paul Alivisatos
Chemical | Energy | Materials | Nanotechnology

The Priestley Medal was awarded to Paul Alivisatos

On Apr. 9, 2021, the American Chemical Society awarded The Priestley Medal to Paul Alivisatos “to recognize distinguished…

Read More The Priestley Medal was awarded to Paul AlivisatosContinue

Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines
Biotechnology | Nanotechnology | Vaccine

Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines

On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…

Read More Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccinesContinue

Baxter Biopharma Solutions announced sterile manufacturing agreement for Novavax COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Baxter Biopharma Solutions announced sterile manufacturing agreement for Novavax COVID-19 vaccine

On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax COVID-19 recombinant…

Read More Baxter Biopharma Solutions announced sterile manufacturing agreement for Novavax COVID-19 vaccineContinue

NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llama
Life Science History | Nanotechnology | NIH

NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llama

On Dec. 22, 2020, the NIH researchers announced they had isolated a set of promising, tiny antibodies, or…

Read More NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llamaContinue

Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
Biotechnology | COVID-19 | Nanotechnology | Therapeutics

Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir

On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…

Read More Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivirContinue

Novavax provided phase 3 COVID-19 vaccine clinical development update
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax provided phase 3 COVID-19 vaccine clinical development update

On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…

Read More Novavax provided phase 3 COVID-19 vaccine clinical development updateContinue

Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
COVID-19 | Nanotechnology | Therapeutics | Vaccine

Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform

On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…

Read More Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platformContinue

Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
Biotechnology | Medical Device | Nanotechnology | Pharmaceutical | Therapeutics

Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups

On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…

Read More Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startupsContinue

Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity
Life Science History | Nanotechnology

Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity

On Sept. 25, 2020, scientists from the University of Oxfordメs Nuffield Department of Medicine published their evaluation of…

Read More Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivityContinue

NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19
COVID-19 | Life Science History | Nanotechnology

NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19

On Sept. 16, 2020, NanoViricides announced that it had nominated a clinical drug candidate for the treatment of…

Read More NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19Continue

Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India

On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which…

Read More Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of IndiaContinue

Novavax initiated phase 2 portion of phase 1/2 clinical trial of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax initiated phase 2 portion of phase 1/2 clinical trial of COVID-19 vaccine

On Aug. 24, 2020, Novavax announced that the first volunteers were enrolled in the Phase 2 portion of…

Read More Novavax initiated phase 2 portion of phase 1/2 clinical trial of COVID-19 vaccineContinue

Novavax initiated efficacy trial of COVID-19 vaccine in South Africa
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax initiated efficacy trial of COVID-19 vaccine in South Africa

On Aug. 17, 2020, Novavax announced the beginning of a Phase 2b clinical trial in South Africa to…

Read More Novavax initiated efficacy trial of COVID-19 vaccine in South AfricaContinue

Page navigation

Previous PagePrevious 1 2 3 4 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search